Amidst Novartis Takeover Rumors, The Medicines Company Announces Positive Cholesterol Data | BioSpace
![Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies - The Lancet Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies - The Lancet](https://www.thelancet.com/cms/attachment/d07735f8-a0cc-4dc0-ace0-73ce06bd61dc/gr1_lrg.jpg)
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies - The Lancet
![Emirates Dermatology Society And Novartis Launch 'Skin To Live In' A Groundbreaking Campaign For People Living With Psoriasis - Health Magazine Emirates Dermatology Society And Novartis Launch 'Skin To Live In' A Groundbreaking Campaign For People Living With Psoriasis - Health Magazine](https://healthmagazine.ae/wp-content/uploads/2017/12/Psoriasis-Infographics-EN-1.jpg)
Emirates Dermatology Society And Novartis Launch 'Skin To Live In' A Groundbreaking Campaign For People Living With Psoriasis - Health Magazine
![Elsberg Syndrome Secondary to Cytomegalovirus Infection in an Immunocompetent Patient | Neurology Neuroimmunology & Neuroinflammation Elsberg Syndrome Secondary to Cytomegalovirus Infection in an Immunocompetent Patient | Neurology Neuroimmunology & Neuroinflammation](https://www.neurology.org/cms/asset/2eb8e30d-f574-4960-aa43-e53bd7d33c48/nxi.10.issue-2.cover.gif)
Elsberg Syndrome Secondary to Cytomegalovirus Infection in an Immunocompetent Patient | Neurology Neuroimmunology & Neuroinflammation
![Pancreatic Cancer Action Network Adaptive Clinical Trial Adds New Investigational Treatment and Additional Sites - Pancreatic Cancer Action Network Pancreatic Cancer Action Network Adaptive Clinical Trial Adds New Investigational Treatment and Additional Sites - Pancreatic Cancer Action Network](https://pancan.org/wp-content/uploads/2022/06/press-New-PrP-Sites.jpg)
Pancreatic Cancer Action Network Adaptive Clinical Trial Adds New Investigational Treatment and Additional Sites - Pancreatic Cancer Action Network
![Lilly-Incyte drug reduces eczema symptoms in treatment-resistant patients | S&P Global Market Intelligence Lilly-Incyte drug reduces eczema symptoms in treatment-resistant patients | S&P Global Market Intelligence](https://www.snl.com/articles/402453154.png)
Lilly-Incyte drug reduces eczema symptoms in treatment-resistant patients | S&P Global Market Intelligence
![Novartis taps Ada Health's AI diagnosis platform for tracking rare, immunological conditions | Fierce Biotech Novartis taps Ada Health's AI diagnosis platform for tracking rare, immunological conditions | Fierce Biotech](https://qtxasset.com/quartz/qcloud5/media/image/fiercebiotech/1620925703/Ada-Health-Test.jpg?VersionId=EFmhfNYrjkc3gswzR2D4Bo4.oDg.zwO)
Novartis taps Ada Health's AI diagnosis platform for tracking rare, immunological conditions | Fierce Biotech
![Plasma neurodegeneration biomarker concentrations associate with glymphatic and meningeal lymphatic measures in neurological disorders | Nature Communications Plasma neurodegeneration biomarker concentrations associate with glymphatic and meningeal lymphatic measures in neurological disorders | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-023-37685-5/MediaObjects/41467_2023_37685_Fig1_HTML.png)